Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.59 |
| ▸ | IGF1R | P08069 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | INSR | P06213 | 3/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202145 | 0.94 | EGFR (0.51) | EGFRIGF1RKCNH2LRRK2CDK1 | |
| SCHEMBL18239602 | 0.90 | EGFR (0.48) | EGFRIGF1RKCNH2LRRK2CDK1 | |
| SCHEMBL18202343 | 0.87 | EGFR (0.45) | EGFRKCNH2INSRALKZAP70 | |
| SCHEMBL23944943 | 0.87 | EGFR (0.64) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL18239603 | 0.87 | EGFR (0.74) | EGFRIGF1RKCNH2INSR | |
| SCHEMBL18202243 | 0.86 | EGFR (0.58) | EGFRMKNK2 | |
| SCHEMBL18202345 | 0.86 | EGFR (0.43) | EGFRKCNH2LRRK2CDK1CDK2 | |
| SCHEMBL19921295 | 0.84 | EGFR (0.42) | EGFRKCNH2LRRK2CDK1CDK2 | |
| SCHEMBL18202259 | 0.84 | EGFR (0.42) | EGFRIGF1RKCNH2INSRALK | |
| SCHEMBL18202149 | 0.83 | EGFR (0.64) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885IGF1R 384/4885KCNH2 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.